TY - JOUR AU - Peters, Solange AU - Zimmermann, Stefan PY - 2014 TI - Targeted therapy in NSCLC driven by HER2 insertions JF - Translational Lung Cancer Research; Vol 3, No 2 (April 2014): Translational Lung Cancer Research (the 10th Congress of Spanish Lung Cancer Group I) Y2 - 2014 KW - N2 - HER2 mutations, largely exon 20 in-frame insertions, have been described as an oncogenic driver alteration in 1% to 4% of NSCLC, exclusively in adenocarcinoma histology. The prognostic implication of these alterations is not known. Phase I and II trial data suggest that afatinib, neratinib and dacomitinib have some activity in this molecular subgroup. No comparative data, or any data regarding the activity of pertuzumab or trastuzumab-emtansine is available. HER2 deregulation either by protein overexpression or gene amplification, has little clinical relevance to date, as trials investigating trastuzumab activity merely suggest a benefit in the very small minority of patients whose tumor highly overexpresses HER2, a subpopulation that amounts to 2% to 6% of mostly adenocarcinomas. UR - http://tlcr.amegroups.com/article/view/2263